SOPHiA GENETICS Chief Scientific Officer Xu Zhenyu sold 4,000 shares at $7.88 per share. The transaction represented about 0.7% of his prior holding, while his reported ownership afterward stood at 552,887 shares, giving investors the disclosed post-sale position and transaction scale.
Key Highlights
- The transaction took place on September 14, 2026, under SEC transaction code S.
- Xu Zhenyu owned 552,887 SOPHiA GENETICS shares after the transaction.
- The sale represented about 0.7% of Xu Zhenyu’s prior share holding.
SOPHiA GENETICS SA (NASDAQ: SOPH) recorded a sale of 4,000 shares at $7.88 per share by Chief Scientific Officer Xu Zhenyu. The transaction sets out the reported price and size of the insider share sale.
Transaction Dated September 14
The transaction date was September 14, 2026. SEC transaction code S identifies the entry as a sale. Xu Zhenyu’s position after the transaction was reported at 552,887 shares. The named seller’s role at SOPHiA GENETICS SA is Chief Scientific Officer.
Sale Equals 0.7% of Prior Holding
The transaction represented about 0.7% of Xu Zhenyu’s prior share holding. That percentage is the disclosed comparison between the sale and his ownership before the transaction. The reported transaction size, price and post-sale holding are the stated measures. The reported comparison is specific to the Chief Scientific Officer’s ownership.
FAQs
Q: What did Xu Zhenyu sell in SOPHiA GENETICS?
A: Xu Zhenyu sold 4,000 SOPHiA GENETICS shares at $7.88 per share. The transaction occurred on September 14, 2026, under transaction code S.
Q: How many SOPHiA GENETICS shares did Xu Zhenyu own afterward?
A: Following the reported sale, Xu Zhenyu’s post-transaction ownership in SOPHiA GENETICS SA was 552,887 shares. The filing reports this ownership figure after the sale of 4,000 shares at $7.88 per share.
Q: What percentage of Xu Zhenyu’s prior holding did the sale represent?
A: The SOPHiA GENETICS transaction represented about 0.7% of Xu Zhenyu’s prior share holding. That percentage measures the sale against his ownership before the transaction.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.